pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Polivy
drug
save

polatuzumab vedotin

Marketedupdated 6mo ago
by Genentech Inc
Approved
community read0 votes

🐶 often sniffed alongside

top 2
  • drugPOLIVY16 co-mentions · 4 sources
  • tagApproval16 co-mentions · 4 sources

indications

investigational
DLBCL

all catalysts(4)

approval · 4
Jun 10, 2019
approval
7y ago
POLIVY (POLATUZUMAB VEDOTIN-PIIQ) — FDA approval
polatuzumab vedotin
→
Sep 18, 2020
approval
6y ago
POLIVY (POLATUZUMAB VEDOTIN-PIIQ) — FDA approval
polatuzumab vedotin
→
Apr 19, 2023
approval
4y ago
POLIVY (POLATUZUMAB VEDOTIN-PIIQ) — FDA approval
polatuzumab vedotin
→
Mar 18, 2026
approval
8mo ago
POLIVY (POLATUZUMAB VEDOTIN-PIIQ) — FDA approval
polatuzumab vedotin
→

Trials studying polatuzumab vedotin

  • phase2Polatuzumab Vedotin, Mosunetuzumab, and Acalabrutinib for the Treatment of Mantle Cell Lymphoma, PAcMan Trialnot yet recruitingn=27
  • phase2Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCLrecruitingn=38
  • phase2A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)recruitingn=594
  • phase2An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphomaactive not recruitingn=211
  • phase1A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignanciesrecruitingn=340
  • phase2TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphomanot yet recruitingn=30
  • phase1Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphomaactive not recruitingn=56
  • phase3A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphomaactive not recruitingn=208

News(7)

  • Epkinly data only one of Genmab's make-or-break readouts ahead of steep sales erosion
    Bracing for patent losses on its cornerstone product Darzalex, Genmab has bet its future on three cancer programs that will deliver pivotal readouts in quick succession.
    biospace · 27d ago
  • Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, more
    New data for Genmab and AbbVie’s bispecific antibody Epkinly wowed analysts and could set the partners up for an expanded approval in diffuse large B cell lymphoma; deals have flowed steadily this…
    biospace · 1mo ago
  • Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trial
    The better-than-expected results could make Epkinly the new “undisputed” treatment standard in newly diagnosed DLBCL, according to one analyst.
    biopharma_dive · 1mo ago
  • AbbVie, Genmab's Epkinly sets ‘new standard of care’ in first-line lymphoma in Phase 3
    AbbVie and Genmab’s bispecific antibody blew analyst expectations out of the water with a 51% improvement in progression-free survival when used alongside a standard frontline regimen in diffuse la…
    biospace · 1mo ago
  • AbbVie, Genmab trot out first-line DLBCL win for Epkinly in challenge to Polivy
    AbbVie and Genmab said their T-cell engager Epkinly passed a late-stage trial in first-line diffuse large B-cell lymphoma, clearing the way for a potential market showdown with Roche’s antibody-dru…
    endpoints · 1mo ago
  • Genentech strikes second Asia deal in a week, betting up to $1B in oncology ADC alliance with DualityBio
    Through its DualityBio deal, Roche's Genentech hopes to create antibody-drug conjugates with payloads that can circumvent growing cancer drug resistance.
    biospace · 2mo ago
  • Roche's late stage pipeline 'so full,' CEO Schinecker not feeling pressure to add on
    Roche has 19 investigational medicines that could launch by 2030—and even if not all of them make it to market, the company is “well set-up for growth into the next decade,” CEO Thomas Schinecker s…
    biospace · 3mo ago
brand
Polivy
generic
polatuzumab vedotin-piiq
indication
Diffuse Large B-Cell Lymphoma
phase
marketed
Data sources
openFDA · ClinicalTrials.gov
last refreshed 8h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?